RxDoctor Payments Data

John Lanzone, MD

Cardiology · Mineola, NYNPI 1407851082

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 32.1% of the total. Reporting peaked in 2023 at $639 and has fallen 60.5% since, to $253 in 2025.

$3,369in general payments, 2019–2025

Across 174 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$560
  • Pfizer$436
  • Esperion Therapeutics, Inc.$269
  • Amgen$264
  • Sanofi-aventis U.S. LLC$131
  • plus $627 from 10 others

What the payments were for

  • Food & beverage$3,369100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,369 in reported general payments places this provider in the 70th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$245,754
Medicare patients
349
Services billed
3,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$192,002
XareltoRivaroxaban91$117,661
EntrestoSacubitril/Valsartan26$37,393
JanuviaSitagliptin Phosphate23$29,865
Metoprolol Succinate284$5,357
Atorvastatin Calcium492$4,064
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,417
Losartan Potassium257$2,316
Levothyroxine Sodium125$2,268
Rosuvastatin Calcium112$2,078
SynthroidLevothyroxine Sodium16$1,613
Amlodipine Besylate220$1,427
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide37$1,155
Atenolol154$1,039
Digoxin31$877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$436$192,002152 claims
Johnson & JohnsonXarelto$1,083$117,66191 claims
NovartisEntresto$560$37,39326 claims
MerckJanuvia$108$29,86523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 112 cardiology providers in New York.

Other cardiology in Mineola

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →